Used in targeted cancer therapy, particularly for gastric and gastroesophageal junction cancers that overexpress the CLDN18.2 protein. It binds specifically to CLDN18.2 on tumor cells, triggering immune-mediated cell destruction through mechanisms like antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Currently evaluated in clinical trials to assess its efficacy in combination with chemotherapy, showing promise in improving progression-free and overall survival in patients with CLDN18.2-positive tumors. Its high specificity allows for targeted treatment with potentially fewer off-target effects compared to conventional chemotherapy.